|
|
|
Insider
Information: |
Leonard Frank X |
Relationship: |
|
City: |
Malvern |
State: |
PA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
160,098 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$2,878,562 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
160,098 |
|
|
Total
Value |
$2,878,562 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
|
|
Stock
price went down : |
|
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Novocure Ltd |
NVCR |
|
2024-03-04 |
160,098 |
2020-09-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-03-04 |
4 |
S |
$16.01 |
$13,448 |
D/D |
(840) |
160,098 |
0 |
% |
|
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-03-01 |
4 |
S |
$16.03 |
$26,909 |
D/D |
(1,679) |
160,938 |
0 |
% |
|
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-02-28 |
4 |
S |
$16.14 |
$33,545 |
D/D |
(2,078) |
162,617 |
0 |
% |
|
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-02-27 |
4 |
A |
$16.30 |
$1,666,659 |
D/D |
102,249 |
164,695 |
0 |
- |
|
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,268 |
|
% |
|
NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
|
2024-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,178 |
|
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-07 |
4 |
AS |
$75.00 |
$625,205 |
D/D |
(8,318) |
54,284 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-03 |
4 |
AS |
$76.16 |
$402,959 |
D/D |
(5,291) |
62,602 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-03 |
4 |
AS |
$77.64 |
$159,859 |
D/D |
(2,059) |
67,893 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,808 |
69,952 |
0 |
- |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-02 |
4 |
AS |
$75.28 |
$63,535 |
D/D |
(844) |
58,144 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-02 |
4 |
AS |
$75.32 |
$309,578 |
D/D |
(4,107) |
58,988 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-03-01 |
4 |
S |
$76.36 |
$128,594 |
D/D |
(1,684) |
63,095 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
18,621 |
64,779 |
0 |
- |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-01-05 |
4 |
AS |
$108.00 |
$4,434,654 |
D/D |
(39,507) |
46,158 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2023-01-05 |
4 |
OE |
$7.15 |
$541,697 |
D/D |
35,209 |
53,341 |
0 |
- |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,830 |
50,456 |
0 |
- |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2022-10-13 |
4 |
AS |
$76.01 |
$513,372 |
D/D |
(6,754) |
43,626 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2022-10-06 |
4 |
AS |
$84.37 |
$569,835 |
D/D |
(6,754) |
50,380 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2022-09-29 |
4 |
AS |
$77.35 |
$522,422 |
D/D |
(6,754) |
57,134 |
0 |
% |
|
NVCR |
Novocure Ltd |
President, CNS Cancers US |
|
2022-09-22 |
4 |
AS |
$77.00 |
$520,058 |
D/D |
(6,754) |
63,888 |
0 |
% |
|
NVCR |
Novocure Ltd |
Chief Development Officer |
|
2022-09-15 |
4 |
AS |
$87.31 |
$1,086,222 |
D/D |
(12,271) |
70,642 |
0 |
% |
|
NVCR |
Novocure Ltd |
Chief Development Officer |
|
2022-09-15 |
4 |
OE |
$7.15 |
$39,447 |
D/D |
5,517 |
82,913 |
0 |
- |
|
NVCR |
Novocure Ltd |
Chief Development Officer |
|
2022-09-09 |
4 |
AS |
$88.00 |
$163,944 |
D/D |
(1,863) |
84,150 |
0 |
% |
|
NVCR |
Novocure Ltd |
Chief Development Officer |
|
2022-09-08 |
4/A |
AS |
$81.48 |
$550,316 |
D/D |
(6,754) |
77,396 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|